LGT Capital Partners LTD. Raises Position in Celgene Co. (CELG)

LGT Capital Partners LTD. boosted its position in shares of Celgene Co. (NASDAQ:CELG) by 24.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 665,466 shares of the biopharmaceutical company’s stock after acquiring an additional 131,880 shares during the period. Celgene accounts for about 3.5% of LGT Capital Partners LTD.’s holdings, making the stock its 5th biggest position. LGT Capital Partners LTD. owned 0.10% of Celgene worth $42,650,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of CELG. HL Financial Services LLC grew its stake in Celgene by 20.5% in the 3rd quarter. HL Financial Services LLC now owns 4,213 shares of the biopharmaceutical company’s stock worth $377,000 after buying an additional 717 shares in the last quarter. FMR LLC grew its stake in Celgene by 26.0% in the 3rd quarter. FMR LLC now owns 10,279,258 shares of the biopharmaceutical company’s stock worth $919,890,000 after buying an additional 2,119,257 shares in the last quarter. ING Groep NV grew its stake in Celgene by 116.3% in the 3rd quarter. ING Groep NV now owns 203,229 shares of the biopharmaceutical company’s stock worth $18,187,000 after buying an additional 109,292 shares in the last quarter. Bangor Savings Bank grew its stake in Celgene by 21.2% in the 3rd quarter. Bangor Savings Bank now owns 18,049 shares of the biopharmaceutical company’s stock worth $1,615,000 after buying an additional 3,157 shares in the last quarter. Finally, IFM Investors Pty Ltd grew its stake in Celgene by 12.3% in the 3rd quarter. IFM Investors Pty Ltd now owns 38,302 shares of the biopharmaceutical company’s stock worth $3,428,000 after buying an additional 4,193 shares in the last quarter. 72.80% of the stock is owned by institutional investors.

NASDAQ:CELG traded down $0.01 during midday trading on Monday, reaching $87.39. 37,694 shares of the stock traded hands, compared to its average volume of 24,947,664. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $107.29. The company has a quick ratio of 1.99, a current ratio of 2.13 and a debt-to-equity ratio of 4.06. The firm has a market capitalization of $61.19 billion, a P/E ratio of 12.77, a P/E/G ratio of 0.46 and a beta of 1.44.



Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 EPS for the quarter, beating the Zacks’ consensus estimate of $2.02 by $0.27. Celgene had a net margin of 19.64% and a return on equity of 108.76%. The company had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.83 billion. As a group, analysts anticipate that Celgene Co. will post 7.45 EPS for the current year.

CELG has been the subject of a number of recent research reports. Cantor Fitzgerald initiated coverage on shares of Celgene in a report on Monday, October 1st. They issued an “overweight” rating and a $100.00 price objective for the company. Zacks Investment Research lowered shares of Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, September 26th. JPMorgan Chase & Co. restated a “buy” rating on shares of Celgene in a report on Thursday, October 11th. Canaccord Genuity lowered shares of Celgene from a “buy” rating to a “hold” rating in a report on Thursday, January 3rd. Finally, Leerink Swann lowered shares of Celgene from an “outperform” rating to a “market perform” rating in a report on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $110.17.

TRADEMARK VIOLATION WARNING: This story was published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://dakotafinancialnews.com/2019/01/14/lgt-capital-partners-ltd-raises-position-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: What is Compound Interest?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply